wolfstreetswinger

OPHT - Strong buy on intriguing news

Pembelian
wolfstreetswinger Diupdate   
NASDAQ:OPHT   None
I recommend to buy a dip or breakup here. I like OPHT for its wild swings on news some might see this as risk but staying in the loop should see us fine and its shares are up considerably on its latest update being that it is set to report registration-ready late-stage trial results for its vision-restoring drug Fovista, which coupled with other drugs already on the market would make a great improvement and it appears that the outcome of those trials will be very good.

I wont go in to great detail as with any investment i recommend to do your own research and analysis before taking any trade but i will update with trial results and fda approvals .

Also to note many analysts are expecting prices to soar back into $90+ region.

Good luck.
Komentar:
TRIALS FAILED STAGE 3
Order dibatalkan

Pernyataan Penyangkalan

Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.